Oncolytics Biotech Announces Appointments to Senior Management Team
CALGARY, Nov. 10, 2011 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC,
NASDAQ:ONCY) ("Oncolytics") today announced the appointment of Gerard
Kennealey, MD as Senior Vice President of Clinical Development and
Chief Medical Officer (CMO). George M. Gill, MD, Oncolytics' CMO since
July 2011, will return to his previous role as Senior Vice President of
Regulatory Affairs and also has been appointed Chief Safety Officer.
"Dr. Kennealey is an excellent addition to our clinical development team
bringing extensive experience with new oncology drug submissions,
regulatory reviews and clinical trial management to his new role," said
Dr. Brad Thompson, President and CEO of Oncolytics. "Dr. Kennealey and
Dr. Gill form a strong team that will advance our proprietary product,
REOLYSIN®, through late-stage clinical testing and global regulatory approvals."
Dr. Kennealey holds a B.S. (Biology) from Boston College and an MD from
the Yale University School of Medicine. Following his medical training
and a decade as a practicing oncologist, Dr. Kennealey worked for
AstraZeneca where he held positions including Vice President, US
Medical Affairs; Vice President, Oncology Clinical Research; and Global
Product Director for Faslodex®. Dr. Kennealey subsequently held an array of progressively senior
positions with other companies in the life sciences industry, as Senior
Vice President & Chief Medical Officer at Eximias Pharmaceuticals;
Senior Vice President, Drug Development at MGI Pharma; and Vice
President of Business Development at Cephalon Inc. Most recently, Dr.
Kennealey was Vice President of Scientific Affairs at Cephalon Inc.
Dr. Gill holds a B.Sc. (Chemistry) from Dickinson College and an MD from
the School of Medicine of the University of Pennsylvania, and is board
certified in pediatrics. He began his career in the pharmaceutical
industry at Hoffman-La Roche, where he held a variety of positions,
including as Director of the Clinical Oncology Group and Associate
Director of Regulatory Affairs. He was subsequently Vice President of
Clinical Research and Vice President of Medical Affairs at Ligand
Pharmaceuticals; Senior Director and Head of U.S. Clinical and Medical
Affairs for ICI Pharmaceuticals (now AstraZeneca); and Vice President
and Head of Worldwide Regulatory Affairs for the Bristol-Myers Company
(now Bristol-Meyers Squibb). Dr. Gill joined Oncolytics in 2002.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN,
its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not
under the Company's control and which may cause actual results,
performance or achievements of the Company to be materially different
from the results, performance or expectations implied by these
forward-looking statements. Such risks and uncertainties include, among
others, the efficacy of REOLYSIN as a cancer treatment, the success and
timely completion of clinical studies and trials, uncertainties related
to the research and development of pharmaceuticals and uncertainties
related to the regulatory process. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking
statements, except as required by applicable laws.